N/A
N=84
Effect of Chicken Egg Antibody (IgY) on Patients With Chronic Gastritis
Chronic Gastritis Caused by Helicobacter Pylori
Bottom Line
View on ClinicalTrials.gov: NCT02721355 ↗Enrolled (actual)
84
Serious AEs
0.0%
Results posted
Jan 2021
Primary outcome: Primary: UBT Values at Baseline and 8 Weeks — 161.64; 158.54; 49.42; 73.37 UBT value
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- GastimunHP (Dietary_supplement)
- Age
- Pediatric, Adult, Older Adult · 2+ yrs
- Sex
- All
- Sponsor
- Immunology Research Institute in Gifu
- Primary completion
- May 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY UBT Values at Baseline and 8 Weeks |
161.64; 158.54; 49.42; 73.37 | — |
| SECONDARY Number of Participants With a Reduction in Severity of Abdominal Pain at 1 and 4 Weeks |
19; 16; 25; 25 | — |
| SECONDARY Number of Participants With a Reduction in Gastrointestinal Symptom Rating Scale (GSRS) Scores at 1 and 4 Weeks |
18; 15; 25; 25 | — |
Summary
H. pylori positive patient volunteers that passed the selection criteria are recruited and divided into a test and a control group. Both groups are treated with a current treatment regime (EAC: Esomeprazole 40 mg/day; Clarithromycin 1000 mg/day; Amoxicillin 2000 mg/day) but only the test group received IgY-containing food supplement as an adjunctive measure for 15 days. The subjects are examined before and 4 weeks after the treatment initiation by Urea Breath Test (UBT) and gastro-endoscopy.
Eligibility Criteria
Inclusion Criteria
- Patients with gastritis or gastric ulcer who are positive to H. pylori
Exclusion Criteria
- People allergic to egg proteins
Data sourced from ClinicalTrials.gov (NCT02721355). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.